SHANGHAI RIGHTONGENE BIOTECHNOLOGY CO., LTD. Financials Shanghai Rightongene Biotechnology Co., Ltd.
Equities
688217
CNE100005212
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.7 CNY | -4.41% |
|
-7.14% | -30.97% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 4,042 | 1,965 | 1,999 | 1,380 | - | - |
| Enterprise Value (EV) 1 | 4,042 | 1,965 | 1,999 | 1,380 | 1,380 | 1,380 |
| P/E ratio | 79 x | 48.4 x | 239 x | 118 x | 98.8 x | 79.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 4.63 x | 7.79 x | 4.44 x | 3.68 x | 3.05 x |
| EV / Revenue | - | 4.63 x | 7.79 x | 4.44 x | 3.68 x | 3.05 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | 2.1 x | 2.11 x | 1.44 x | 1.42 x | 1.4 x |
| Nbr of stocks (in thousands) | 55,577 | 55,577 | 55,856 | 55,856 | - | - |
| Reference price 2 | 72.72 | 35.35 | 35.78 | 24.70 | 24.70 | 24.70 |
| Announcement Date | 2/25/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 424.3 | 256.6 | 311 | 375 | 453 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | 71.71 | -7.244 | 8 | 11 | 15 |
| Operating Margin | - | 16.9% | -2.82% | 2.57% | 2.93% | 3.31% |
| Earnings before Tax (EBT) 1 | - | 71.48 | -9.895 | 13 | 15 | 19 |
| Net income 1 | 46.01 | 40.47 | 8.124 | 12 | 14 | 17 |
| Net margin | - | 9.54% | 3.17% | 3.86% | 3.73% | 3.75% |
| EPS 2 | 0.9200 | 0.7300 | 0.1500 | 0.2100 | 0.2500 | 0.3100 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/25/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 4.43% | 0.86% | 1.21% | 1.45% | 1.73% |
| ROA (Net income/ Total Assets) | - | 3.44% | 0.76% | 1.1% | 1.3% | 1.4% |
| Assets 1 | - | 1,177 | 1,063 | 1,091 | 1,077 | 1,214 |
| Book Value Per Share 2 | - | 16.90 | 16.90 | 17.10 | 17.40 | 17.70 |
| Cash Flow per Share 2 | - | 1.310 | 0.8100 | 1.160 | 0.7400 | 1.120 |
| Capex 1 | - | 107 | 109 | 125 | 125 | 125 |
| Capex / Sales | - | 25.12% | 42.43% | 40.19% | 33.33% | 27.59% |
| Announcement Date | 2/25/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
24.7
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.97% | 191M | |
| -4.13% | 12.37B | |
| -1.48% | 8.37B | |
| +9.61% | 5.84B | |
| +25.61% | 5.4B | |
| -4.58% | 4.37B | |
| -51.80% | 3.23B | |
| +16.25% | 2.8B | |
| +30.25% | 2.26B | |
| -4.08% | 1.87B |
- Stock Market
- Equities
- 688217 Stock
- Financials Shanghai Rightongene Biotechnology Co., Ltd.